 |
|
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Myung Ji Goh, Dong Hyun Sinn
Clin Mol Hepatol. 2022;28(3):380-395. Published online 2022 Jan 13 DOI: https://doi.org/10.3350/cmh.2021.0366
|
|
Citations to this article as recorded by
 Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis
Jie Wang, Kaijie Qiu, Songsheng Zhou, Yichao Gan, Keting Jiang, Donghuan Wang, Haibiao Wang
Annals of Medicine.2025;[Epub] CrossRef Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after vira
Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
Clinical and Molecular Hepatology.2025; 31(1): e64. CrossRef The Impact of Statins on the Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib or Lenvatinib
Ji Eun Han, Jisu Kim, Jae Youn Cheong, Soon Sun Kim, Sun Gyo Lim, Min Jae Yang, Choong-Kyun Noh, Gil Ho Lee, Jung Woo Eun, Bumhee Park, Hyo Jung Cho
Cancers.2024; 16(2): 249. CrossRef Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
Jiao Wang, Chengyu Liu, Ronghua Hu, Licheng Wu, Chuanzhou Li
Frontiers in Pharmacology.2024;[Epub] CrossRef Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study
Hyunjae Shin, Seung Up Kim, Byeong Geun Song, Youngsu Park, Yunmi Ko, Jeayeon Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Dong Hyun Sinn, Yoon Jun Kim
Hepatology Research.2024; 54(7): 627. CrossRef SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong
Scientific Reports.2024;[Epub] CrossRef Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(3): 326. CrossRef Chemoprevention of hepatocellular carcinoma associated with metabolic dysfunction-associated steatotic liver disease: an updated review
Averie Dickinson, Amreen Dinani, Kara Wegermann
Hepatoma Research.2024;[Epub] CrossRef Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
Paul Y. Kwo
Clinical and Molecular Hepatology.2024; 30(4): 714. CrossRef Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: T
Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip
Clinical and Molecular Hepatology.2024; 30(4): 970. CrossRef Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks
Amani Elshaer, Blanca C. Lizaola-Mayo
Life.2024; 14(12): 1701. CrossRef Statin Monotherapy Not Inferior to Aspirin or Combined Aspirin and Statins Reducing the Incidences of Cirrhosis, HCC, and Mortality in MAFLD/MASH Patients: A Population Cohort Study
Chern-Horng Lee, Yu-Han Huang, Tzu-Ju Hsu, Tzung-Hai Yen, Sen-Yung Hsieh
International Journal of General Medicine.2024; Volume 17: 6495. CrossRef Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis
Niccolò Bitto, Gabriele Ghigliazza, Stanislao Lavorato, Camilla Caputo, Vincenzo La Mura
Journal of Clinical Medicine.2023; 12(3): 934. CrossRef Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clinical and Molecular Hepatology.2023; 29(Suppl): S220. CrossRef The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma
Dongming Li, Donghui Cao, Yingnan Cui, Yuanlin Sun, Jing Jiang, Xueyuan Cao
Frontiers in Pharmacology.2023;[Epub] CrossRef MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George
Journal of Gastroenterology.2023; 58(10): 947. CrossRef AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Amit G. Singal, Josep M. Llovet, Mark Yarchoan, Neil Mehta, Julie K. Heimbach, Laura A. Dawson, Janice H. Jou, Laura M. Kulik, Vatche G. Agopian, Jorge A. Marrero, Mishal Mendiratta-Lala, Daniel B. Brown, William S. Rilling, Lipika Goyal, Alice C. Wei, Ta
Hepatology.2023; 78(6): 1922. CrossRef Statin use and the risk of hepatocellular carcinoma among patients with chronic hepatitis B: an emulated target trial using longitudinal nationwide population cohort data
Dong Hyun Sinn, Danbee Kang, Yewan Park, Hyunsoo Kim, Yun Soo Hong, Juhee Cho, Geum-Youn Gwak
BMC Gastroenterology.2023;[Epub] CrossRef
|